Clodi Martin, Abrahamian Heidemarie, Brath Helmut, Brix Johanna, Drexel Heinz, Fasching Peter, Föger Bernhard, Francesconi Claudia, Fröhlich-Reiterer Elke, Harreiter Jürgen, Hofer Sabine E, Hoppichler Friedrich, Huber Joakim, Kaser Susanne, Kautzky-Willer Alexandra, Lechleitner Monika, Ludvik Bernhard, Luger Anton, Mader Julia K, Paulweber Bernhard, Pieber Thomas, Prager Rudolf, Rami-Merhar Birgit, Resl Michael, Riedl Michaela, Roden Michael, Saely Christoph H, Schelkshorn Christian, Schernthaner Guntram, Sourij Harald, Stechemesser Lars, Stingl Harald, Toplak Hermann, Wascher Thomas C, Weitgasser Raimund, Winhofer-Stöckl Yvonne, Zlamal-Fortunat Sandra
ICMR - Institute for Cardiovascular and Metabolic Research, Johannes Kepler Universität Linz, 4040, Linz, Österreich.
Abteilung für Innere Medizin mit Diabetologie, Gastroenterologie und Hepatologie, Rheumatologie und Intensivmedizin, Konventhospital der Barmherzigen Brüder Linz, Seilerstätte 2, 4021, Linz, Österreich.
Wien Klin Wochenschr. 2019 May;131(Suppl 1):27-38. doi: 10.1007/s00508-019-1471-z.
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.
高血糖显著促成糖尿病患者的并发症。虽然生活方式干预仍然是疾病预防和治疗的基石，但大多数2型糖尿病患者最终将需要药物治疗来控制血糖。关于最佳治疗效果、安全性以及心血管效应的个体目标的定义非常重要。在本指南中，我们为医疗保健专业人员提供了最新的循证最佳临床实践数据。
